ROADMAP aims to create the conditions for an open collaboration among stakeholders that yields consensual and efficient uses of real world evidence for the benefit of Alzheimer's Disease patients and their caregivers.


Led by Professor John Gallacher at the University of Oxford’s Department of Psychiatry, ROADMAP aims to provide the foundation for a Europe-wide real world evidence (RWE) platform in Alzheimer’s Disease by piloting multimodal data integration tools and engaging with all key stakeholder groups for consensual definition of patient outcomes, tools and methods that are actionable and relevant. ROADMAP will leverage best practice and exploit synergies with other projects and initiatives at national and European levels in pursuit of scalable and transferable solutions for dataset characterisation, outcome classification, data standards, data sourcing, software application and guidelines on the handling and interpretation of RWE data.

In parallel, the project will deepen understanding of the ethical, legal and social implications and health economics impact of real world evidence platforms for a meaningful contribution to the Big Data for Better Outcomes programme in IMI2.

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020 (“ROADMAP”). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

 European Federation of Pharmaceutical Industries and Associations (EFPIA)   European Commission   Innovative Medicines Initiative (IMI)

Latest blog posts